TG Therapeutics | TGTX

Stock Price
32.21
Daily Change
0.32 1.00%
Monthly
16.28%
Yearly
46.21%
Q3 Forecast
31.94

Peers Price Chg Day Year Date
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Ardelyx 6.52 -0.05 -0.76% 16.43% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Biogen 140.67 0.73 0.52% -30.02% Sep/05
Corcept Therapeutics 69.36 -0.01 -0.01% 101.75% Sep/05
Dynavax Technologies 10.06 0.08 0.80% -8.79% Sep/05
Gilead Sciences 115.05 2.28 2.02% 46.10% Sep/05
J&J 178.43 -0.33 -0.18% 8.51% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

TG Therapeutics traded at $32.21 this Friday September 5th, increasing $0.32 or 1.00 percent since the previous trading session. Looking back, over the last four weeks, TG Therapeutics gained 16.28 percent. Over the last 12 months, its price rose by 46.21 percent. Looking ahead, we forecast TG Therapeutics to be priced at 31.94 by the end of this quarter and at 31.15 in one year, according to Trading Economics global macro models projections and analysts expectations.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).